Bleakley Financial Group LLC grew its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 3.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,672 shares of the conglomerate’s stock after acquiring an additional 687 shares during the quarter. Bleakley Financial Group LLC’s holdings in Danaher were worth $4,745,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. FMR LLC increased its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. boosted its holdings in shares of Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after acquiring an additional 397,671 shares during the last quarter. Finally, Union Bancaire Privee UBP SA bought a new stake in shares of Danaher in the fourth quarter worth approximately $74,551,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling
In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Get Our Latest Stock Report on DHR
Danaher Trading Down 1.4 %
Shares of DHR stock opened at $211.92 on Thursday. The stock’s 50-day moving average price is $234.50 and its 200-day moving average price is $252.68. Danaher Co. has a 12-month low of $210.04 and a 12-month high of $281.70. The stock has a market capitalization of $153.07 billion, a price-to-earnings ratio of 40.14, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the company posted $2.09 earnings per share. Equities research analysts predict that Danaher Co. will post 7.77 EPS for the current fiscal year.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is 20.45%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- Growth Stocks: What They Are, What They Are Not
- Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead?
- Market Cap Calculator: How to Calculate Market Cap
- RTX and Lockheed Martin: Buy 1 for Today and 1 for Tomorrow
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Must-Have ETFs Set to Dominate This Quarter
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.